TAVR for All? The Surgical Perspective

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

TAVR for All? The Surgical Perspective. / Zhang, Xiling; Puehler, Thomas; Frank, Derk; Sathananthan, Janarthanan; Sellers, Stephanie; Meier, David; Both, Marcus; Blanke, Philipp; Seoudy, Hatim; Saad, Mohammed; Müller, Oliver J.; Sondergaard, Lars; Lutter, Georg.

I: Journal of Cardiovascular Development and Disease, Bind 9, Nr. 7, 223, 2022.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Zhang, X, Puehler, T, Frank, D, Sathananthan, J, Sellers, S, Meier, D, Both, M, Blanke, P, Seoudy, H, Saad, M, Müller, OJ, Sondergaard, L & Lutter, G 2022, 'TAVR for All? The Surgical Perspective', Journal of Cardiovascular Development and Disease, bind 9, nr. 7, 223. https://doi.org/10.3390/jcdd9070223

APA

Zhang, X., Puehler, T., Frank, D., Sathananthan, J., Sellers, S., Meier, D., Both, M., Blanke, P., Seoudy, H., Saad, M., Müller, O. J., Sondergaard, L., & Lutter, G. (2022). TAVR for All? The Surgical Perspective. Journal of Cardiovascular Development and Disease, 9(7), [223]. https://doi.org/10.3390/jcdd9070223

Vancouver

Zhang X, Puehler T, Frank D, Sathananthan J, Sellers S, Meier D o.a. TAVR for All? The Surgical Perspective. Journal of Cardiovascular Development and Disease. 2022;9(7). 223. https://doi.org/10.3390/jcdd9070223

Author

Zhang, Xiling ; Puehler, Thomas ; Frank, Derk ; Sathananthan, Janarthanan ; Sellers, Stephanie ; Meier, David ; Both, Marcus ; Blanke, Philipp ; Seoudy, Hatim ; Saad, Mohammed ; Müller, Oliver J. ; Sondergaard, Lars ; Lutter, Georg. / TAVR for All? The Surgical Perspective. I: Journal of Cardiovascular Development and Disease. 2022 ; Bind 9, Nr. 7.

Bibtex

@article{6bc8256fb831455aaf3d226ce3c187a7,

title = "TAVR for All? The Surgical Perspective",

abstract = "In spite of the noninferiority of transcatheter aortic valve replacement (TAVR) in high- and intermediate-risk patients, there are still obstacles that need to be overcome before the procedure is further expanded and clinically integrated. The lack of evidence on the long-term durability of the bioprostheses used for TAVR remains of particular concern. In addition, surgery may be preferred over TAVR in patients with bicuspid aortic valve (BAV) or with concomitant pathologies such as other valve diseases (mitral regurgitation/tricuspid regurgitation), aortopathy, and coronary artery disease. In this review, we discuss and summarize relevant data from clinical trials, current trends, and remaining obstacles, and provide our perspective on the indications for the expansion of TAVR.",

keywords = "aortic valve stenosis, high risk, intermediate risk, low risk, surgical aortic valve replacement (SAVR), transcatheter aortic valve implantation (TAVI), transcatheter aortic valve replacement (TAVR)",

author = "Xiling Zhang and Thomas Puehler and Derk Frank and Janarthanan Sathananthan and Stephanie Sellers and David Meier and Marcus Both and Philipp Blanke and Hatim Seoudy and Mohammed Saad and M{\"u}ller, {Oliver J.} and Lars Sondergaard and Georg Lutter",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

doi = "10.3390/jcdd9070223",

language = "English",

volume = "9",

journal = "Journal of Cardiovascular Development and Disease",

issn = "2308-3425",

publisher = "M D P I AG",

number = "7",

}

RIS

TY - JOUR

T1 - TAVR for All? The Surgical Perspective

AU - Zhang, Xiling

AU - Puehler, Thomas

AU - Frank, Derk

AU - Sathananthan, Janarthanan

AU - Sellers, Stephanie

AU - Meier, David

AU - Both, Marcus

AU - Blanke, Philipp

AU - Seoudy, Hatim

AU - Saad, Mohammed

AU - Müller, Oliver J.

AU - Sondergaard, Lars

AU - Lutter, Georg

PY - 2022

Y1 - 2022

N2 - In spite of the noninferiority of transcatheter aortic valve replacement (TAVR) in high- and intermediate-risk patients, there are still obstacles that need to be overcome before the procedure is further expanded and clinically integrated. The lack of evidence on the long-term durability of the bioprostheses used for TAVR remains of particular concern. In addition, surgery may be preferred over TAVR in patients with bicuspid aortic valve (BAV) or with concomitant pathologies such as other valve diseases (mitral regurgitation/tricuspid regurgitation), aortopathy, and coronary artery disease. In this review, we discuss and summarize relevant data from clinical trials, current trends, and remaining obstacles, and provide our perspective on the indications for the expansion of TAVR.

AB - In spite of the noninferiority of transcatheter aortic valve replacement (TAVR) in high- and intermediate-risk patients, there are still obstacles that need to be overcome before the procedure is further expanded and clinically integrated. The lack of evidence on the long-term durability of the bioprostheses used for TAVR remains of particular concern. In addition, surgery may be preferred over TAVR in patients with bicuspid aortic valve (BAV) or with concomitant pathologies such as other valve diseases (mitral regurgitation/tricuspid regurgitation), aortopathy, and coronary artery disease. In this review, we discuss and summarize relevant data from clinical trials, current trends, and remaining obstacles, and provide our perspective on the indications for the expansion of TAVR.

KW - aortic valve stenosis

KW - high risk

KW - intermediate risk

KW - low risk

KW - surgical aortic valve replacement (SAVR)

KW - transcatheter aortic valve implantation (TAVI)

KW - transcatheter aortic valve replacement (TAVR)

UR - http://www.scopus.com/inward/record.url?scp=85135558264&partnerID=8YFLogxK

U2 - 10.3390/jcdd9070223

DO - 10.3390/jcdd9070223

M3 - Review

C2 - 35877585

AN - SCOPUS:85135558264

VL - 9

JO - Journal of Cardiovascular Development and Disease

JF - Journal of Cardiovascular Development and Disease

SN - 2308-3425

IS - 7

M1 - 223

ER -

ID: 328426120